ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,050.61
-0.39%
Dow Jones
43,449.90
-0.61%
US Dollar vs MXN
20.20612
0.14%
Brent Oil
73.115
0.01%
Bitcoin
103,954.60
-2.07%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arcturus Therapeutics Holdings Inc (ARCT)

  7. Arcturus Therapeutics Holdings Inc (ARCT) Noticias

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT)

NASDAQ
15.73
-0.51
(-3.14%)
Cerrado 18 Diciembre 3:00PM
Delayed by 15 minutes
15.97
0.24
(1.53%)
Fuera de horario: 6:38PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

ARCT Noticias

Solo noticias oficiales

Form 8-K - Current report
Edgar (US Regulatory)
07 Noviembre 2024
ARCT (-3.14%)

Form 8-K - Current report
Edgar (US Regulatory)
13 Agosto 2024
ARCT (-3.14%)

ARCT Discussion

Ver más
Monksdream Monksdream 3 meses hace
ARCT a buy again
👍️0
Monksdream Monksdream 4 meses hace
That awful Cathie Wood has been a recent buyer
👍️0
Monksdream Monksdream 4 meses hace
ARCT 10Q due AUGUST5
👍️0
Monksdream Monksdream 9 meses hace
ARCT 10Q due March 7
👍️0
Monksdream Monksdream 10 meses hace
ARCT new 52 week high
👍️0
Monksdream Monksdream 1 año hace
Arcturus Therapeutics (ARCT)
icon-fall
19%
Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
Monksdream Monksdream 1 año hace
Arcturus Therapeutics Holdings Inc NASDAQ: ARCT

GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform







and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
IOUBLOKE1 IOUBLOKE1 3 años hace
Silence is golden ARC
👍️0
IOUBLOKE1 IOUBLOKE1 3 años hace
Wow big after hours green buy
👍️0
IOUBLOKE1 IOUBLOKE1 3 años hace
Spike delivers in Canada 400 million does
👍️0
make it happen make it happen 3 años hace
http://archive.fast-edgar.com/20210812/A2Z2M22C3Z2232K222JN2CZ272FUV22SE232/ another company that directs them selling out potentially seems like a big negative along with many downgrades over $20.00 less than current PPS
👍️0
Smknf250 Smknf250 3 años hace
I don’t see any filing that reflects that. Where do you see it?
👍️0
make it happen make it happen 3 años hace
Director sold 725,000 shares @ $55.44 and 25,000 @ $45.83 total of 800,000 shares

Capitalization at it's finest, run for the hills. imho

bounce off 30's then into 20's
👍️0
make it happen make it happen 3 años hace
B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.
👍️0
make it happen make it happen 3 años hace
$1.40* opps

1-7 R/S

Sold drug in a few years will prob do another one sadly
👍️0
make it happen make it happen 3 años hace
Don't forget was like $1.10 at one point. Only 2 mil Revenue VS 2.7 expected.. while losing 56.4 mil in the second quarter or over 225,000,000 million loss for the year.

-$225,000,000 vs maybe 4 mil on a good year

Downgraded to under preform

Sold the drug now have nada

Also had nice size R/S in the past
👍️0
make it happen make it happen 3 años hace
Posted Revenue of $2 million vs estimated 2.7 mil.

Loss of $56.4 million second quarter only.

Huge differences

Sold the drug... No mo

Down graded to underperform
👍️0
make it happen make it happen 3 años hace
Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Oh no...
👍️0
dinogreeves dinogreeves 3 años hace
ARCT the next NVAX.
👍️0
Cosa Cosa 3 años hace
might be getting squeezed, the float is so low.
👍️0
Cosa Cosa 3 años hace
wow this is pumping
👍️0
Atown62 Atown62 4 años hace
Thoughts now?
👍️0
Clemdane Clemdane 4 años hace
Still long here. This is a looong term buy. Disappointing that we got that massive haircut, but we've had them before and recovered. It's the nature of this volatile sector.
👍️0
Atown62 Atown62 4 años hace
Well?
👍️0
lecorb lecorb 4 años hace
In TDAmeritrade. TIPRANKS 7 SCROE PT: $88.25
Analyst Ratings, Moderate Buy! Last actualitation!
Based on the 10 sell-sidetooltipClick this button to read the definition of sell-side analysts who offered a 12-month price target in the last three months. Analysts predict a(n) 122.80% increase from today.
Kumaraguru Raja
Brookline Capital Markets
5Stars target $102.00rankingBuyanalystAction
Maintained date 2 days ago
analyst
Steven Seedhouse
Raymond James
5 Stars target ranking Hold analystAction Downgraded date 2 days ago
analyst
Yasmeen Rahimi
Piper Sandler
5Star target $140.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Seamus Fernandez
Guggenheim
5 Stars target -- ranking Buy analystAction Maintained date
2 days ago
Madhu Kumar
Robert W. Baird
5 Stars target $69.00 ranking Hold analystAction Downgraded
date
2 days ago
analyst
Elemer Piros
Roth Capital
5 Stars target $77.00 ranking Sell analystAction Maintained
date 2 days ago
Mayank Mamtani
B.Riley Financial
5 Stars target $138.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Yigal Nochomovitz
Citigroup
5Stars target $133.00 ranking Buy analystAction Maintained
date 17 days ago
👍️0
sanderburwil sanderburwil 4 años hace
Nope- was just a good “tax dump day” excuse today. Not holding- but really tempted- can only see upwards from here. Cathy woods didn’t sell a share today. Tells you something..
👍️0
Willymon Willymon 4 años hace
ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.


The ol' "buy the rumor, sell the news" strikes again.


Or, today is last day to sell for 2020 taxes -- Dump day.


Take your pick.


It's a pandemic market and more crazy and unexpected things to come.


Remember, ARCT has a lot more to offer than just COVID solutions.


Their tech enables many other biotech companies delivery and replication methods.


ARCT has established a 52-wk high of $130.


Many think it will go past that.

👍️0
ClayTrader ClayTrader 4 años hace
* * $ARCT Video Chart 12-29-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Clemdane Clemdane 4 años hace
Wish I had flipped it. Hindsight is 20/20.
👍️0
Willymon Willymon 4 años hace
ARCT - Me as well. Been in-n-out four times with profits every time.


When I talk to others they never heard of ARCT.


Ready for the next leg.
👍️0
Clemdane Clemdane 4 años hace
I'm still in - going to see where the ride takes me
👍️0
Willymon Willymon 4 años hace
ARCT - Still going but nobody on iHub seems aware.


Some on Stocktwits saying this is going to $500-700.


I get 10x plays often, but this is a big 10x for sure.
👍️0
whytestocks whytestocks 4 años hace
JUST IN: $ARCT Why Arcturus Therapeutics Stock Soared Today

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

In case you are interested ARCT - Why Arcturus Therapeutics Stock Soared Today
👍️0
whytestocks whytestocks 4 años hace
Breaking News: $ARCT Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

Find out more ARCT - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
👍️0
Clemdane Clemdane 4 años hace
I'm more amazed that anyone posted on this board. But I agree on the breakout!
👍️0
Willymon Willymon 4 años hace
ARCT - In it to win it.
👍️0
Biggiee Biggiee 4 años hace
Breakout! Blue skies.
👍️0
Clemdane Clemdane 4 años hace
Wow! Someone posted on the ARCT board. Thank you very much. I like your chart. I will put my faith in Fibonacci!
👍️0
TFMG TFMG 4 años hace
$ARCT | #ArcturusTherapeutics Breakout Alert



Potential long above $63.00
Upside Fibonacci target zone $76.00


👍️0
Clemdane Clemdane 4 años hace
Hello silent ARCT board. Just a message to say I am still here! Still long ARCT.
👍️0
Clemdane Clemdane 5 años hace
That's what I thought. Thank you.
👍️0
Willymon Willymon 5 años hace
$ARCT - Doesn't look like the two are comparable.

$ARCT's self replicating delivery method along with the protein they are developing to block the keyholes in the host (humans) the spikes on viruses need to infect the host is a unique approach. Can't spike into a receiving host keyhole, no infection or replication. Game over.

$ARCT would be one shot as a cure for nearly all viruses, including the common flu.

I'm also a little weary with all these biotechs promising cures so soon.

Rhinovirus(Flu/common cold) still has no vaccine which they have been working to cure since the 1950's.

$ARCT thinks they have the total solution.

👍️0
Clemdane Clemdane 5 años hace
Hey do you know anywhere with a good competitive analysis of ARCT vs. the Oxford University vaccine?
👍️0
Clemdane Clemdane 5 años hace
It's truly incredible. I'm thrilled to be here.
👍️0
Willymon Willymon 5 años hace
$ARCT - News out today. How you feeling about those 13's now?
👍️0
pix pix 5 años hace
Shortly they hopefully will give some details to preclinical studies...
If positive, watch out...
👍️0
Willymon Willymon 5 años hace
$ARCT - Singapore has set and is setting the example to follow in all this.

The fact that they selected $ARCT to develop a cure is very telling.

Arcturus announced that it is partnering with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to develop a COVID-19 vaccine to prevent infection by the coronavirus. The government of Singapore will pay for the vaccine's development -- $10 million to be paid part up-front, part upon achievement of unspecified "development milestones." And Singapore will get first dibs on any vaccines produced (plus potential royalties on vaccine sales outside of Singapore).Link>

👍️0
pix pix 5 años hace
If approved in Singapore, they will get access to many Asian countries....
👍️0
Clemdane Clemdane 5 años hace
Incredible. I have it in an IRA. Going to try to get more.
👍️0
Willymon Willymon 5 años hace
$ARCT - $13.90 is sooner. Nobody here is even aware of them. And, with only 1100 on stocktwits, nobody there is aware.

If you buy at $50 and it goes to $110, you're still in profit. But, now we're into the "What IF" game. Have to be long on $ARCT.

If they come up with the Covid-19 vaccine, then that also means they also cured thousands of other viruses.

Their method is to provide humans with a way to clog the keyholes that the spikes on viruses need to plug into to infect and replicate.

They don't patent some of their methods on purpose because a patent must show exactly how something works. This is to their advantage so other biotech companies have to go figure it out on their own. Trade secret.

👍️0

Su Consulta Reciente

NASDAQ
ARCT
Arcturus Therapeutics
NASDAQ
DMLP
Dorchester Minerals
EU
RNOCA
Renault SA Regular Inter...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados